Division of NantWorks LLC
Latest From NantCell LLC
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter.
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.
Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- NantWorks LLC
- Senior Management
- Patrick Soon-Shiong, PhD, CEO
- Contact Info
Phone: (310) 883-1300
9920 Jefferson Blvd.
Culver City, CA 90232
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.